2020.10.07 Qin Siyuan published a review article in international academic journal STTTOn 7th October 2020, Mr. Qin Siyuan published a review article entitled "Emerging role of tumor cell plasticity in modifying therapeutic response." In the international academic journal Signal Transduct Target Ther (impact factor 13.493). For a long time, tumor drug resistance has been a bottleneck problem in clinical treatment. In the face of this problem, a large number of basic and clinical studies have fully demonstrated the important role of resistance-conferring mutations in the process. However, treatment strategies developed for these mutations (especially targeted therapy), Targeted therapy), which has yielded encouraging initial results, has failed to shake off treatment failure caused by new mutations. In other words, a single strategy targeting mutations are not sufficient to overcome the development of resistance at all. Therefore, more and more scientists have turned their attention to the study of the non-mutational drug resistance mechanism. A large body of evidence suggests that Tumor cells typically switch from one form of phenotype to another -- Tumor cell plasticity -- in order to escape drug attack, and that phenotypic switching is a significant characteristic of non-mutant drug resistance. It is noteworthy that the process of embryonic development, especially the abnormal reactivation of its related pathways (Wnt, Hedgehog, Notch, etc.), is strikingly similar to this plasticity change. Based on these similarities, this paper systematically summarized the molecular mechanisms of cell plasticity in the regulation of tumor drug resistance, epithelial-mesenchymal transition, and epithelial-mesenchymal transition. EMT, the acquisition and maintenance of stem cells, and trans-differentiation, etc., were introduced to summarize and discuss a variety of potential therapeutic plans targeting or utilizing tumor cell plasticity, aiming to provide thinking and theoretical support for optimizing existing therapeutic strategies and even developing new therapeutic strategies. In short, only continuous "change" in strategy can prevent "change" (high plasticity) of tumor cells and fundamentally improve the status of treatment tolerance in tumor patients. Only 'change' can prevent 'change', and make it changeless ". |